2020
DOI: 10.1016/j.jaip.2019.07.016
|View full text |Cite
|
Sign up to set email alerts
|

Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
46
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 53 publications
(49 citation statements)
references
References 30 publications
2
46
0
1
Order By: Relevance
“…Intriguingly, the risk of OAEs appears to be circumscribed to AD patients. Indeed, their incidence was very similar to placebo in dupilumab clinical trials for asthma, rhinosinusitis with nasal polyps and eosinophilic oesophagitis 2,5,10,11,19 . The severity of OAEs associated with dupilumab is variable, rarely leading to treatment discontinuation in clinical trials 12–17,19 and small series of cases 20–29 .…”
Section: Introductionmentioning
confidence: 87%
See 1 more Smart Citation
“…Intriguingly, the risk of OAEs appears to be circumscribed to AD patients. Indeed, their incidence was very similar to placebo in dupilumab clinical trials for asthma, rhinosinusitis with nasal polyps and eosinophilic oesophagitis 2,5,10,11,19 . The severity of OAEs associated with dupilumab is variable, rarely leading to treatment discontinuation in clinical trials 12–17,19 and small series of cases 20–29 .…”
Section: Introductionmentioning
confidence: 87%
“…Its safety has been evaluated in 15 randomized double‐blinded, placebo‐controlled phase 2 and phase 3 clinical trials 2–17 . The safety profile of dupilumab was favourable, and only 1–3% of patients had to stop treatment because of adverse events in AD phase 3 clinical trials 15,17,18 .…”
Section: Introductionmentioning
confidence: 99%
“…Reduction in itch score of four points was defined as a clinically significant response. In the first two, 16 week, studies 36% and 41% achieved this reduction in itch with dupilumab, compared to 9.5% and 12.3% with placebo. In the third study, 36% of people maintained their response at 52 weeks.…”
Section: Atopic Dermatitismentioning
confidence: 87%
“…The phase 3 moderate-severe asthma study data was later analyzed to examine whether patients with self-reported chronic rhinosinusitis symptoms were more likely to have an improvement in their asthma outcomes. 16 A significant limitation of the study was that data on nasal polyposis had not been collected. Patients with chronic rhinosinusitis generally had higher blood eosinophils and FE NO at baseline but lower rates of allergic sensitization.…”
Section: Chronic Rhinosinusitismentioning
confidence: 99%
“…One notable example is dupilumab, a human monoclonal antibody (mAb) targeting IL-4Ra, which reduces IL-4 signaling, effectively lowering severe asthma in patients with uncontrolled moderate-to-severe asthma with or without chronic rhinosinusitis. 94 Dupilumab is currently approved by the Food and Drug Administration and European Medicines Agency for treating moderate-to-severe AD, asthma, and chronic rhinosinusitis with nasal polyposis. 95 Dupilumab is also effective in reducing clinical signs and symptoms of AD and in moving the skin transcriptome of patients toward a nonlesional phenotype.…”
Section: Biologicsmentioning
confidence: 99%